Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient
We present a case report of a 63-year-old female health care worker who is 15 years status post double lung transplant and six years status post living related donor kidney transplant who is healthy on a chronic immunosuppression regimen including prednisone, mycophenolate, and tacrolimus who receiv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207638/full |
| _version_ | 1797789200115826688 |
|---|---|
| author | James Long Mithil Soni Pawel Muranski Maureen J. Miller Cathleen Conry-Cantilena Valeria De Giorgi |
| author_facet | James Long Mithil Soni Pawel Muranski Maureen J. Miller Cathleen Conry-Cantilena Valeria De Giorgi |
| author_sort | James Long |
| collection | DOAJ |
| description | We present a case report of a 63-year-old female health care worker who is 15 years status post double lung transplant and six years status post living related donor kidney transplant who is healthy on a chronic immunosuppression regimen including prednisone, mycophenolate, and tacrolimus who received the SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) primary series and had poor initial humoral response to the COVID-19 mRNA vaccine, then demonstrated a robust, sustained immune response against S1 and S2 antigens for over seven months after receiving the recommended vaccine doses, including booster dose, without developing COVID-19 or other serious adverse events. Her immune response to vaccination indicates effective formation of anti-spike T cell memory despite chronic immunosuppression. This case report provides a comprehensive characterization of her immune response to this SARS-CoV-2 vaccination series. As vaccine effectiveness data is updated, and as better understanding of immune response including hybrid immunity emerges, these findings may reassure that recipients of SOTs may be capable of durable immune responses to emerging variants of SARS-CoV-2. |
| first_indexed | 2024-03-13T01:47:21Z |
| format | Article |
| id | doaj.art-35f402aa1acf411e918f70be63a5e4c0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T01:47:21Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-35f402aa1acf411e918f70be63a5e4c02023-07-03T05:28:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.12076381207638Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipientJames Long0Mithil Soni1Pawel Muranski2Maureen J. Miller3Cathleen Conry-Cantilena4Valeria De Giorgi5Infectious Diseases Section, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United StatesColumbia Center for Translational Immunology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, United StatesColumbia Center for Translational Immunology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, United StatesInfectious Diseases Section, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United StatesInfectious Diseases Section, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United StatesInfectious Diseases Section, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United StatesWe present a case report of a 63-year-old female health care worker who is 15 years status post double lung transplant and six years status post living related donor kidney transplant who is healthy on a chronic immunosuppression regimen including prednisone, mycophenolate, and tacrolimus who received the SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) primary series and had poor initial humoral response to the COVID-19 mRNA vaccine, then demonstrated a robust, sustained immune response against S1 and S2 antigens for over seven months after receiving the recommended vaccine doses, including booster dose, without developing COVID-19 or other serious adverse events. Her immune response to vaccination indicates effective formation of anti-spike T cell memory despite chronic immunosuppression. This case report provides a comprehensive characterization of her immune response to this SARS-CoV-2 vaccination series. As vaccine effectiveness data is updated, and as better understanding of immune response including hybrid immunity emerges, these findings may reassure that recipients of SOTs may be capable of durable immune responses to emerging variants of SARS-CoV-2.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207638/fullCOVID-19SARS-CoV-2 vaccinehumoral immunitycellular immunityimmunocompromisedsolid organ transplant |
| spellingShingle | James Long Mithil Soni Pawel Muranski Maureen J. Miller Cathleen Conry-Cantilena Valeria De Giorgi Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient Frontiers in Immunology COVID-19 SARS-CoV-2 vaccine humoral immunity cellular immunity immunocompromised solid organ transplant |
| title | Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient |
| title_full | Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient |
| title_fullStr | Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient |
| title_full_unstemmed | Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient |
| title_short | Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient |
| title_sort | case report kinetics and durability of humoral and cellular response of sars cov 2 messenger rna vaccine in a lung and kidney transplant recipient |
| topic | COVID-19 SARS-CoV-2 vaccine humoral immunity cellular immunity immunocompromised solid organ transplant |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207638/full |
| work_keys_str_mv | AT jameslong casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient AT mithilsoni casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient AT pawelmuranski casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient AT maureenjmiller casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient AT cathleenconrycantilena casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient AT valeriadegiorgi casereportkineticsanddurabilityofhumoralandcellularresponseofsarscov2messengerrnavaccineinalungandkidneytransplantrecipient |